Navigation Links
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
Date:11/10/2008

NOVATO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's"). CHU d'Angers has received a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health, to fund the two-year, multi-center Phase II clinical trial in Huntington's patients. Under the terms of the agreement, Raptor will provide clinical supplies of DR Cysteamine for the trial.

In May 2008, the Office of Orphan Product Development at the U.S. Food and Drug Administration ("FDA") granted orphan drug designation to Raptor for cysteamine-based drugs, including DR Cysteamine, for the treatment of Huntington's.

Ted Daley, President of Raptor's Clinical Division, stated, "We look forward to collaborating with CHU d'Angers to evaluate DR Cysteamine in patients with Huntington's Disease. Our formation work with DR Cysteamine in conjunction with the CHU d'Angers studies in Huntington's fits our strategic plan to explore multiple potential indications for cysteamine and DR Cysteamine. Cysteamine has demonstrated neuroprotective effects in preclinical studies, and the planned Phase II study led by CHU d'Angers could confirm existing data regarding cysteamine's safety and potential efficacy in Huntington's."

Professor Dominique Bonneau, M.D., Ph.D. of CHU d'Angers, commented, "We are encouraged by the existing studies that indicate cysteamine's potential as a neuroprotectant for treating Huntington's, and we believe that Raptor's formulation could offer a better tolerated drug for this patient population. We are confident that this trial will enhance our
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update on Targeting Platforms
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Raptor Pharmaceuticals Provides Update of Product Programs
6. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
7. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
8. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
11. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2009)...0 Calixa Therapeutics Inc. today a...l of CXA-101 in patients with complicated urinary ..., parenteral cephalosporin antibiotic with excelle...domonas aeruginosa , including drug resistant isol...ial treatment for serious bacterial infections in ...
(Date:6/29/2009)... Seeks to Assess RSV Burden in Outpatient Setting ...to Pediatric Research , , GAITHERSBURG, Md., ...ance its commitment to pediatric research with tod...ective study designed to assess the burden of resp...s 32-to-35 weeks gestational age (GA) in outpatien...
(Date:6/29/2009)...dominal surgery patients achieved primary and seco...29 AcelRx Pharmaceuticals, Inc. to...se 2 clinical study evaluating the safety and effi... management of acute post-operative pain in patien...on. Compared to placebo, patients receiving ARX-01...
(Date:6/29/2009)...England, June 29 Vantia Therapeuti... novel, small molecule drugs,targeting large, und...ts from,a Phase IIa clinical trial of its lead de...al showed that oral VA106483 was successful in pro...effect in patients, as determined by,increased os...
Breaking Medicine Technology:Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Impact of floods on soils 7909 1Impact of floods on soils 7909 2Heartburn Sufferers Find Lasting Relief With TUMS 28R 29 Dual Action 42045 1Heartburn Sufferers Find Lasting Relief With TUMS 28R 29 Dual Action 42045 2Heartburn Sufferers Find Lasting Relief With TUMS 28R 29 Dual Action 42045 3Autism Software Developer Announces Hiring of Susan DuRant as Director of Education 42042 1Autism Software Developer Announces Hiring of Susan DuRant as Director of Education 42042 2AAID Hails Florida Court Verdict Allowing Advertising of Bona Fide Dental Credentials 42038 1AAID Hails Florida Court Verdict Allowing Advertising of Bona Fide Dental Credentials 42038 2
... 6, 2007 - ZIOPHARM Oncology, Inc.,(NASDAQ: ZIOP) ...cutive Officer, will present at the C.E. Unterberg...on Thursday, July 12, 2007,at 2:30 p.m. ET at the ...provide an overview of the Company and an update o...tion will be webcast live and can be accessed by,v...
...IRE)--Jul 5, 2007 - GTC,Biotherapeutics, Inc. ("GT...x, Ph.D., GTC,s Chairman and CEO, is scheduled to,...uring the C.E.,Unterberg, Towbin Emerging Growth L...ing held at the Mandarin Oriental Hotel, New,York,...on will be webcast live and can be accessed by,log...
Other Medicine Technology:ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference 2GTC Biotherapeutics to Webcast Corporate Presentation at the C.E.,Unterberg, Towbin Emerging Growth Life Opportunities Conference 2
(Date:7/3/2009)...ortunity for you to change your life - After just ...ll experience a noticeable relief from the terribl...ol levels and blood pressure will return to normal... finally be freed from the health concerns that ac... Miami, FL (PRWEB) July 3, 2...
(Date:7/2/2009)...nology Institute (BTI) have made a novel discovery...ecule" (FAIM), protects both immune and liver cell...heir research is published in the current journal ...ts, Jianxin Huo, Ph.D., and Shengli Xu, Ph.D., als...ipulated for clinical application and proposed the...
(Date:7/2/2009)... Pro-life forces won an important battle yesterday...te law regulating that abortion centers must prope...(also known as the "abortion pill") in order to pr...The ruling came in Rogers v. Planned Parenthood ,...equiring that those administering RU-486 comply wi...
(Date:7/2/2009)..., expert says , , THURSDAY, July 2 (Heal... species of wildlife, which need to be protected t...ancer is one of the leading health concerns for hu... deaths. But we now understand that cancer can kil...se McAloose, chief pathologist for the Wildlife Co...
Breaking Medicine News(10 mins):Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 2Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 3Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 4Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of 'Abortion Pill' 2Health News:Cancer Endangers Some Wildlife Species 2
...h is a common malady that many suffer from, it oft...ario. In an all out effort to overcome it those st... stuffs, which are notably notorious in causing ba...ment for Halitosis, to cover it up, chewing gums, ...
...eavor to unravel the mysteries in the gray matter ...natural to humans, and needs no introduction – SEL... people more selfish than the rest of us? While so... of selflessness! Scientists have clued in on a t...
...rwent sheer misery, caught between the devil and t...daughter who was in dire need of emergency mental/...was put on hold for a year, before any form of cou...red acute eating disorder and she had a history of...
...ealth officials, the kid who died due to kidney fa...ain in the tainted spinach that has caused a// cou...old boy, Kyle Allgood, from Chubbuck, Idaho, who d... fatality of the E. coli bacteria outbreak that ha...
Other Medicine News:
Narrow smooth jaws. Serrated handle with polished finish.
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish.
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model.
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle.
Medicine Products: